Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
SGN-TGT is a nonfucosylated monoclonal antibody that targets TIGIT, thereby preventing its interaction with CD112 and CD155 and enhancing the interaction of CD112 and CD155 with CD226 expressed on immune cells, which may lead to activation of an anti-tumor immune response (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): CT265).
|DrugClasses||TIGIT Antibody 19|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Axitinib + PF-06801591 + SGN-TGT||Axitinib PF-06801591 SGN-TGT||0||1|
|Pembrolizumab + SGN-TGT||Pembrolizumab SGN-TGT||0||1|